Literature DB >> 3373238

Antibodies against saline-soluble components of skeletal muscle in myasthenia gravis.

A Komiyama1, I Kamo, S Furukawa, S Akazawa, K Hirayama, E Satoyoshi.   

Abstract

Antibodies against phosphate-buffered-saline extracts (SE) of non-acetylcholine receptor (AChR) skeletal muscle antigens were found in patients with myasthenia gravis (MG). The antigenicity of SE was distributed in three fractions with molecular masses of over 200 kDa, 90-150 kDa and 7-14 kDa on gel filtration. These fractions shared common antigenicities. Further analysis of 90-150 kDa fractions on sodium dodecyl sulphate polyacrylamide gel electrophoresis showed five major bands, ranging from 105 kDa to 275 kDa. The antibodies against SE were detected in 52% (58/112) of the MG patients; incidence and titres were higher in the thymoma group (n = 21; 90% and 0.872 respectively) than in the non-thymoma group (n = 91; 43% and 0.200, P less than 0.001). In patients without a thymoma, these antibodies were frequently observed in late-onset disease and the severe generalized form (P less than 0.01). In 4 of 7 ocular MG patients without anti-AChR antibodies, low but appreciable levels of anti-SE antibodies were found. In 73% (11/15) of generalized MG patients treated with prednisolone and thymectomy, anti-SE antibody titres changed in association with those of anti-AChR antibodies and with the clinical course. Both antibody titres increased synchronously in patients who developed crises.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373238     DOI: 10.1007/bf00314348

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

Review 1.  Myasthenia gravis (first of two parts).

Authors:  D B Drachman
Journal:  N Engl J Med       Date:  1978-01-19       Impact factor: 91.245

2.  Studies in myasthenia gravis. Correlation of antibody immunofluorescence with clinical course.

Authors:  K E Osserman; L B Weiner
Journal:  N Engl J Med       Date:  1965-09-16       Impact factor: 91.245

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  [Corticosteroid therapy combined with thymectomy in myasthenia gravis].

Authors:  N Ito; K Hirayama; M Baba; Y Yamaguchi; N Kuroda
Journal:  Rinsho Shinkeigaku       Date:  1983-04

Review 5.  Immunology of acetylcholine receptors in relation to myasthenia gravis.

Authors:  A Vincent
Journal:  Physiol Rev       Date:  1980-07       Impact factor: 37.312

6.  Antiglobulin consumption test with sera from patients with myasthenia gravis.

Authors:  J A Aarli; O Tönder
Journal:  Clin Exp Immunol       Date:  1970-07       Impact factor: 4.330

7.  Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination.

Authors:  J A Aarli; A K Lefvert; O Tönder
Journal:  J Neuroimmunol       Date:  1981-12       Impact factor: 3.478

8.  Myasthenia gravis. Antibodies to an acid-soluble antigen in striated muscle.

Authors:  J A Aarli
Journal:  Clin Exp Immunol       Date:  1972-03       Impact factor: 4.330

9.  Monoclonal antibody to acetylcholine receptor: cell line established from thymus of patient with Myasthenia gravis.

Authors:  I Kamo; S Furukawa; A Tada; Y Mano; Y Iwasaki; T Furuse; N Ito; K Hayashi; E Satoyoshi
Journal:  Science       Date:  1982-02-19       Impact factor: 47.728

10.  IgG subclass distribution of myasthenia gravis thymoma-associated antiskeletal muscle antibodies.

Authors:  C I Smith; J A Aarli; L Hammarström; M A Persson
Journal:  Neurology       Date:  1984-08       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.